BNP Paribas Financial Markets raised its holdings in shares of Chemed Corporation (NYSE:CHE - Free Report) by 14.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 35,024 shares of the company's stock after purchasing an additional 4,430 shares during the quarter. BNP Paribas Financial Markets owned 0.25% of Chemed worth $14,985,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also bought and sold shares of the business. Eukles Asset Management lifted its position in Chemed by 0.4% during the third quarter. Eukles Asset Management now owns 6,031 shares of the company's stock valued at $2,700,000 after purchasing an additional 24 shares during the last quarter. Cim LLC lifted its holdings in shares of Chemed by 1.1% in the 3rd quarter. Cim LLC now owns 2,139 shares of the company's stock worth $958,000 after acquiring an additional 24 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Chemed by 71.4% in the 3rd quarter. Smartleaf Asset Management LLC now owns 60 shares of the company's stock worth $27,000 after acquiring an additional 25 shares during the last quarter. Merit Financial Group LLC lifted its holdings in shares of Chemed by 4.0% in the 3rd quarter. Merit Financial Group LLC now owns 940 shares of the company's stock worth $421,000 after acquiring an additional 36 shares during the last quarter. Finally, Renasant Bank lifted its holdings in shares of Chemed by 5.0% in the 3rd quarter. Renasant Bank now owns 824 shares of the company's stock worth $369,000 after acquiring an additional 39 shares during the last quarter. Institutional investors own 95.85% of the company's stock.
Chemed Stock Up 1.9%
Shares of NYSE CHE opened at $440.67 on Friday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 0.83 and a current ratio of 0.85. The firm has a market capitalization of $5.85 billion, a price-to-earnings ratio of 24.01, a PEG ratio of 1.66 and a beta of 0.54. The stock has a 50 day moving average price of $409.41 and a 200 day moving average price of $424.56. Chemed Corporation has a 52-week low of $365.20 and a 52-week high of $565.66.
Chemed (NYSE:CHE - Get Free Report) last announced its quarterly earnings results on Thursday, April 23rd. The company reported $5.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.30 by $0.35. The firm had revenue of $657.51 million during the quarter, compared to analyst estimates of $659.22 million. Chemed had a return on equity of 27.18% and a net margin of 10.23%.Chemed's quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.63 earnings per share. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. Sell-side analysts expect that Chemed Corporation will post 22.3 earnings per share for the current year.
Chemed Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 16th. Shareholders of record on Thursday, May 28th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Thursday, May 28th. This represents a $2.40 dividend on an annualized basis and a yield of 0.5%. Chemed's dividend payout ratio (DPR) is 13.08%.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on CHE shares. Royal Bank Of Canada raised their target price on shares of Chemed from $422.00 to $436.00 and gave the stock a "sector perform" rating in a report on Monday, April 27th. Zacks Research upgraded shares of Chemed from a "strong sell" rating to a "hold" rating in a report on Monday, April 27th. Weiss Ratings upgraded shares of Chemed from a "sell (d+)" rating to a "hold (c-)" rating in a report on Wednesday, April 29th. Wall Street Zen upgraded shares of Chemed from a "hold" rating to a "buy" rating in a report on Sunday, May 31st. Finally, Oppenheimer lowered their target price on shares of Chemed from $580.00 to $500.00 and set an "outperform" rating for the company in a report on Friday, February 27th. Two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Chemed presently has a consensus rating of "Hold" and an average target price of $501.50.
Read Our Latest Analysis on CHE
Insider Buying and Selling
In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the firm's stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $421.13, for a total transaction of $842,260.00. Following the transaction, the chief executive officer owned 90,219 shares of the company's stock, valued at approximately $37,993,927.47. This trade represents a 2.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 3.33% of the company's stock.
About Chemed
(
Free Report)
Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.
The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.
Featured Articles
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.